Primary carnitine deficiency is caused by a defect in the OCTN2 carnitine transporter encoded by the SLC22A5 gene. It can cause hypoketotic hypoglycemia or cardiomyopathy in children, and sudden death in children and adults. 
INTRODUCTION
Primary carnitine deficiency (MIM# 212140) is an autosomal recessive disorder of the carnitine cycle resulting in defective fatty acid oxidation (Longo, Frigeni, & Pasquali, 2016) . The incidence of primary carnitine deficiency varies with a frequency of approximately 1:40,000 newborns in Japan, 1:37,000-1:100,000 newborns in Australia, and 1:142,000 in the USA (Koizumi et al., 1999; Longo et al., 2016; Therrell, Lloyd-Puryear, Camp, & Mann, 2014; Wilcken, Wiley, Hammond, & Carpenter, 2003) . The highest incidence of primary carnitine deficiency (1:300) is in the Faroe Islands, an archipelago in the North Atlantic that remained geographically isolated for many centuries, where about 5% of the population is carrier for an abnormal allele Rasmussen et al., 2014b; Rasmussen, Kober, Lund, & Nielsen, 2014a; Steuerwald et al., 2017) .
The gene for primary carnitine deficiency, SLC22A5 (MIM# 603377), spans about 30 kb on chromosome 5q31 (chr5:132,369,752-132,395,614, hg38) and encodes for the organic cation transporter novel 2 (OCTN2) carnitine transporter Tamai et al., 1998; Wu, Prasad, Leibach, & Ganapathy, 1998) . OCTN2 was identified in 1998 for its homology to the organic cation transport novel 1 (OCTN1) (Tamai et al., 1998; Wu et al., 1999; Wu, et al., 1998) . OCTN1 and OCTN2 are part of the SLC22 family of membrane transporters, along with organic anion and cation transporters (Burckhardt & Wolff, 2000; Frigeni, Iacobazzi, Yin, & Longo, 2016; Longo et al., 2016) . OCTN2 operates as a Na + -independent organic cation transporter as well as a high affinity (K m = 2.9 ± 0.7 M) Na + -dependent carnitine transporter Tamai et al., 1998; Wang, Meadows, & Longo, 2000b; Wu et al., 1999) . Over 150 genetic variants are described in the SLC22A5 mutation database (https://www.arup.utah.edu/database/OCTN2/OCTN2_display.php), of which 86 are pathogenic (including missense, nonsense, indels, frame-shifting, splice-site altering mutations, and one large gene deletion).
Defective carnitine transport results in urinary carnitine wasting, low serum carnitine levels (<9 M, normal 25-50 M), and decreased intracellular carnitine accumulation . Patients with primary carnitine deficiency lose most (10%-95%) of the filtered carnitine in urine, and their heterozygous parents lose two to three times the normal amount, explaining their mildly reduced plasma carnitine levels . Since carnitine is required for the transfer of long-chain fatty acids from the cytoplasm to the mitochondrial matrix for subsequent -oxidation, the lack of carnitine impairs the ability to use fat as energy source during periods of metabolic stress . If carnitine supplements are not promptly started, patients with primary carnitine deficiency can present with an acute metabolic decompensation early in life, or later in life with skeletal and cardiac myopathy or sudden death from arrhythmia Rose et al., 2012; Wang, Kelly, Cowan, & Longo, 2000a) . Siblings of affected children had only mild developmental delays or were asymptomatic Spiekerkoetter et al., 2003; Wang et al., 2001) .
With the advent of expanded newborn screening, infants with primary carnitine deficiency or their affected mothers can be identified by very low levels of free carnitine . The diagnosis of primary carnitine deficiency can be biochemically confirmed by demonstration of low free carnitine levels in plasma with reduced renal reabsorption (less than 90%), and normal renal function with no abnormalities in the urine organic acids (although a non-specific dicarboxylic aciduria has been reported during acute attacks) Scaglia et al., 1998) . Given the possibility of a maternal disorder causing primary or secondary carnitine deficiency, plasma and urine carnitine, plasma acylcarnitine profile, and urine organic acids should be evaluated in the mother as well when carnitine levels are low in the newborn screening . The diagnosis can be definitively confirmed by verifying reduced carnitine transport activity (<20% of normal controls) in skin fibroblasts from the patient or by mutational analysis of the SLC22A5 gene .
The measurement of carnitine transport in cultured fibroblasts is a very reliable method to confirm the diagnosis of primary carnitine deficiency, but is time demanding and requires a skin biopsy . For this reason, molecular analysis (sequencing and deletion/duplication analysis) of the 10 exons of the SLC22A5 gene and exon/intron boundaries in DNA obtained from blood is now the firstline test for diagnostic confirmation .
Here, the reliability of DNA testing is compared to functional studies in fibroblasts to confirm the diagnosis of primary carnitine deficiency in 95 subjects. In addition, several novel missense mutations are expressed in heterologous cells to confirm their pathogenicity.
MATERIALS AND METHODS

Patients and membrane transport
All studies were approved by the IRB of the University of Utah.
Patients were referred for diagnostic confirmation either after symptomatic presentation or after identification by newborn screening programs. Some of the patients reported in this study were previously individually described (Amat di San Filippo & Longo, 2004 ; Amat di Amat di San Filippo, Taylor, Mestroni, Botto, & Longo, 2008; Amat di San Filippo, Wang, & Longo, 2003; De Biase et al., 2012; Filippo, Ardon, & Longo, 2011; Rose et al., 2012; Schimmenti et al., 2007; Wang et al., 2000a; Wang et al., 2001; Wang et al., 2000b; Wang, Taroni, Garavaglia, & Longo, 2000c; Wang, Ye, Ganapathy, & Longo, 1999) . Fibroblasts from patients with primary carnitine deficiency were obtained by skin biopsy for diagnostic purposes. They were grown in Dulbecco's Modified Eagle Medium (Thermo Fisher Scientific Inc., Waltham, MA) supplemented with 12% fetal bovine serum (Sigma-Aldrich Corporation, St. Louis, MO), 2 mM L-glutamine (Thermo Fisher Scientific Inc.), 100 U/ml penicillin-streptomycin (GE Healthcare Life Sciences HyClone Laboratories, South Logan, UT), 2.5 g/ml amphotericin B solution (GE Healthcare Life Sciences HyClone Laboratories). 3 H-Carnitine (0.5 M) transport was measured for 4 hr at 37 • C in adherent cells using the cluster-tray method (Scaglia, Wang, & Longo, 1999; Wang et al., 2000b) . Non-saturable transport was measured in the presence of 2 mM cold carnitine and was subtracted from total transport to obtain saturable transport (Scaglia et al., 1999; Wang et al., 2000b) .
Values are reported as means ± SE of six independent determinations obtained in two separate experiments.
DNA analysis and molecular techniques
Genomic DNA was extracted from fibroblasts or peripheral blood by standard methods. GenBank sequence AB016625.1 was used as reference for the gene, NM_003060.2 was used as the reference sequence for the cDNA, and NP_001295051.1 for the protein. Nucleotide numbering uses the A of the ATG translation initiation start site as nucleotide +1. The 10 exons of the SLC22A5 gene including exon/intron boundaries were amplified by PCR using a total of 10 primer pairs tailed with universal M-13 forward and reverse sequences. Amplification was verified by automated gel electrophoresis in the HDA-GT12 TM Genetic Analyzer. PCR fragments were purified with ExoSap-IT (USB) and bi-directionally sequenced using BigDye-Terminator v.1.1 cycle sequencing kit and capillary electrophoresis in the ABI3730. Generated sequences were aligned to reference sequence (GenBank AB016625.1) using Mutation Surveyor v.4.0 (Softgenetics 100 Oakwood Ave # 350, State College, PA 16803) to detect mutations (Wang et al., 2001) . Multiplex ligation-dependent probe amplification (MLPA) analysis was performed to detect large deletions within the SLC22A5 gene. Each DNA sample (400 ng) was analyzed using the SALSA MLPA P076 ACADVL-SLC22A5 Probemix for SLC22A5 (MRC-Holland, Amsterdam, The Netherlands) following the manufacturer's recommendations (https://mlpa.com/WebForms/WebFormMain.aspx).
Missense variants identified in patients with primary carnitine deficiency were re-created in the OCTN2-EGFP expression vector by site-directed mutagenesis using the Quick Change system (Agilent Technologies Inc., Santa Clara, CA) following the manufacturer's instructions (Amat di San Filippo et al., 2003; Wang et al., 2000b) . The final plasmids were sequenced to confirm the presence of the mutation and the absence of PCR artifacts and stably transfected into Chinese Hamster Ovary (CHO) cells. The plasmid contained the neomycin-resistance gene and cells were selected for resistance to G418 (Geneticin, 0.8 mg/ml) for 3 weeks before testing.
A mass culture including different clones was then used for functional studies. Confocal microscopy was used to confirm protein production, since in our expression vector the OCTN2 transporter is tagged with the green fluorescent protein (Wang et al., 2000b) . CHO cells were grown in Ham's F12 Nutrient Mixture (Thermo Fisher Scientific Inc.) supplemented with 6% fetal bovine serum (Sigma-Aldrich Corporation), 2 mM L-glutamine (Thermo Fisher Scientific Inc.), 100 U/ml penicillin-streptomycin (GE Healthcare Life Sciences HyClone Laboratories), and 2.5 g/ml amphotericin B solution (GE Healthcare Life Sciences HyClone Laboratories). Carnitine (0.5 M) transport was measured at 37 • C with the cluster-tray method as previously described (Amat di San Filippo et al., 2003; Wang et al., 2000b) .
In silico analysis of missense mutations
The missense variants identified and expressed in CHO cells were evaluated using Sorting Intolerant From Tolerant (SIFT, https://sift.jcvi.org/www/SIFT_enst_submit.html) and Polymorphism Phenotyping Version v2.2.2r398 (POLYPHEN-2, https://genetics.bwh.
harvard.edu/pph2/index.shtml) software programs for variant evaluation.
Estimate of allele frequency
The Exome Aggregation Consortium Browser Beta (ExAC, https://exac.broadinstitute.org/) and the Genome Aggregation Database (gnomAD, https://gnomad.broadinstitute.org/) were used to determine the allele frequency of the variants identified in the SLC22A5 gene (Lek et al., 2016) .
RESULTS
Functional and molecular characterization of fibroblasts from patients with primary carnitine deficiency
Carnitine transport was measured in skin fibroblasts from 358 subjects referred for possible primary carnitine deficiency (Figure 1) . A wide range of carnitine transport activity was observed in these cells with a nearly continuous distribution of activity from 0% of control to values above that measured in matched controls. A reduction of carnitine transport to 20% or less than paired normal control fibroblasts was used as cut-off for the diagnosis of primary carnitine deficiency, since all of our patients whose fibroblasts had carnitine transport below 20% of normal controls were not able to maintain free carnitine level ≥9 mol/l (normal 25-50 M) without supplements . Cells from 140 out of 358 subjects (39%) had carnitine transport activity below 20% of paired normal controls.
Molecular studies (sequencing of the 10 exons and flanking regions of the SLC22A5 gene encoding the OCTN2 carnitine transporter and deletion/duplication analysis) were performed in 95 out of 140 of the affected subjects. Table 1 shows carnitine transport activity in Non-saturable transport, measured in the presence of 2 mM cold carnitine, was subtracted from total transport to obtain saturable carnitine transport. Transport activity was normalized to the one of simultaneous normal controls (100% activity). Each bar represents the average of six observations in two separate experiments with the sample numbered from 1 (lowest activity) to 358 (highest activity) indicated on the x-axis. Carnitine transport activity of 20% or less of normal controls was indicative of primary carnitine deficiency (continuous line). Fibroblasts from some of the subjects had carnitine transport higher than their paired normal controls (100% activity, dashed line) fibroblasts of the 95 patients diagnosed with primary carnitine deficiency along with the variants identified in their SLC22A5 gene. Among the 72 variants identified, 48 were missense, nine caused a frameshift, eight were nonsense, two were in-frame deletions, one was a synonymous variant, and four were localized in flanking regions of the SLC22A5 gene. Overall, the most frequent mutation was c.136C > T (p.Pro46Ser), which was identified in 13 out of 190 alleles. This mutation has been identified in asymptomatic or minimally symptomatic (easy fatigability, muscle pain with exercise, fasting intolerance) adult women Schimmenti et al., 2007) and in a mother (compound heterozygous p.Pro46Ser/p.Asn32Ser) who suffered repeated episodes of cardiac arrest requiring placement of a defibrillator, episodes that resolved after her diagnosis and initiation of carnitine therapy (De Biase et al., 2012) . This mutation (p.Pro46Ser) reduces, but does not abolish carnitine transport and affects glycosylation and maturation to the plasma membrane of the OCTN2 carnitine transporter (Filippo et al., 2011; Longo et al., 2016) . This and other similar missense mutations seem protective against early clinical manifestations of primary carnitine deficiency, but can still be associated with fatal cardiac arrhythmia leading to sudden death (De Biase et al., 2012; Longo et al., 2016; Rose et al., 2012) . Molecular analysis identified causative variants in 84% of the affected alleles, but failed to identify significant variations in six out of 95 patients, and a second mutation in 19 out of 95 patients (Table 2) , despite a functional diagnosis of primary carnitine deficiency. 
Expression of SLC22A5 variants in CHO cells
NOT FOUND
Carnitine transport activity was measured in fibroblasts from subjects referred for possible primary carnitine deficiency ( Figure 1 ) and expressed as percent of normal activity. The 10 exons and flanking regions of the SLC22A5 gene encoding the OCTN2 carnitine transporter were sequenced and subjected to deletion/duplication analysis in patients whose fibroblasts had <20% of normal transport activity (transport activity is reported in the second column). Variations from the standard sequence (NM_003060.2) are reported in columns 3-10. No causative variants were identified in 16% of the alleles (NOT FOUND).
TA B L E 2 Molecular studies in patients with primary carnitine deficiency
Number of patients 95
Number of alleles 190
Alleles with unknown mutations 31/190 (16%)
Patients with no identified variant in one allele
19/95 (20%)
Patients with no identified variant in either alleles 6/95 (6%)
Sequencing and deletion/duplication analysis of all 10 exons of the SLC22A5 gene and flanking regions was performed in 95 patients diagnosed with primary carnitine deficiency because of a low level of carnitine transport in fibroblasts (activity < 20% of matching normal controls). No variants were identified in 31 out of 190 (16%) of the alleles sequenced. For six out of 95 (6%) affected patients, no variants were identified in either alleles, whereas for 19 out of 95 (20%) affected patients, no variant was identified in one allele.
since it does not require a skin biopsy and is relatively rapid. Among samples received for molecular analysis (including the 95 patients who had carnitine transport analyzed in fibroblasts), 133 different variants were identified, with 33 being novel (Table 3A) . Of the 133 variants identified, 90 were missense, 16 caused a frameshift, 14 were nonsense, eight affected splicing, two were in-frame deletions of single amino acids, one was a ∼1.6 Mb deletion encompassing the entire OCTN2 gene , one was a 113 bp deletion encompassing the initiation codon of exon 1 , and one was a syn- OCTN2 carnitine transporter, assumed to be 100% (Table 3A) . Carnitine transport was reduced to less than 20% of control in 73/92 variants, indicating that these amino acid substitutions significantly impaired carnitine transport activity. Figure 2 ), including transmembrane and hydrophilic regions in a manner similar to pathogenic missense variants (filled circles in Figure 2 ). While we cannot exclude that some of these changes might represent mutations (they could affect splicing which was not directly tested here, or they (Table 3B) . From these data, 1:221 (0.0045289) alleles contained either one of the missense mutations expressed in this study or a mutation causing the premature insertion of a stop codon or affecting splicing in the SLC22A5 gene (Table 3B and Supplementary   Table S1 ). Note that one normal subject reported in the gnomAD browser was homozygous for the p.Tyr449Asp variant (Table 3B ). This variant reduced carnitine transport to about 17% of normal OCTN2
Frequency of tested variants in the general population
and has only been identified in one heterozygous patient whose fibroblasts had about 50% of normal carnitine transport (carrier of primary carnitine deficiency) (Amat di San Filippo & Longo, 2004) . We cannot exclude that the subject homozygous for this variant has a late-onset form of primary carnitine deficiency.
Given the frequency of pathogenic variants in the normal population (p), the predicted frequency of individuals with two abnormal alleles (p 2 ) in a general population would be 1.6817 × 10 −5 or 1:59,465.
Variant analysis software
Polyphen-2 and SIFT are software programs commonly used to predict the pathogenicity of missense variants. The 90 missense variants and two in-frame deletions whose carnitine transport was tested in CHO cells were evaluated using these software programs and the results compared (Table 3C ). Both programs were effective in separating benign from damaging variants (P = 0.0005 for Polyphen-2 and P = 0.0009 for SIFT using analysis of variance; Table 4 ). However, about 20% of the variants were incorrectly assigned by either program, with a more marked error in the prediction of benign variants (Table 4 ).
When only variants in which the two programs provided a concordant interpretation (74 out of 92) were analyzed, the correct prediction rate increased to 86% (Table 4) .
DISCUSSION
Primary carnitine deficiency is a recessive condition caused by mutations in the OCTN2 carnitine transporter encoded by the SLC22A5 gene . The defective OCTN2 carnitine transporter is expressed in fibroblasts and these cells can be used for diagnostic confirmation . By looking at a large number of diagnostic samples on which functional studies were performed, there was a continuum of distribution of carnitine transport activity, from 0% in some patients up to 1.5 times normal in certain subjects Table 3B shows the frequency in normal individuals in the ExAC Browser Beta and in the gnomAD of the alleles found in our patients along with the number of normal individual homozygous for a specific allele. 1:221 alleles contained either one of the missense mutations expressed in this study or a mutation causing the premature insertion of a stop codon or affecting splicing in the SLC22A5 gene. (C) The 90 missense variants and two in-frame deletions whose carnitine transport was tested in CHO cells were evaluated for pathogenicity using the F I G U R E 2 Schematic of the OCTN2 carnitine transporter with location of the 92 variants expressed in CHO cells. The OCTN2 carnitine transporter is composed of 557 amino acids. Hydropathy analysis and conservation with other organic cation transporters indicates that the transporter forms 12 transmembrane spanning domains (rectangles) with both the N-and C-termini facing the cytoplasm. Glycosylation sites are indicated by branching (Filippo et al., 2011) . The 92 OCTN2 variants identified and expressed in CHO cells are indicated by circles. Mutations reducing carnitine transport to 20% or less than wild-type when expressed in CHO cells are indicated by full circles; variants retaining more that 20% residual activity are indicated by empty circles. The A142S and R488H mutations (indicated by black stripes circles) impair carnitine transport when in cis on the same allele, but not alone (Amat di San fibroblast strains had no evidence of a carnitine uptake defect and that carnitine transport activity was above 60% of normal (the highest levels we have seen in a carrier) in about 70 patients. This suggests that in many cases confirmatory testing might have been requested immediately at the time of initial presentation, without following over time plasma carnitine levels to remove cases of secondary carnitine deficiency (in most cases nutritional).
Genetic analysis identified a number of missense variants, some of which decreased substantially transport activity, others that caused only a modest or no impairment ( and in some cases, sudden death at any age . At the same time, a subject wrongly diagnosed with the disease will have to face an unnecessary lifelong therapy with carnitine supplements .
Unlike mutations causing the premature insertion of a stop codon or affecting splicing, the interpretation of missense variants found by molecular analysis can be difficult and requires additional studies. Here we expressed 90 missense variants and 2 in-frame deletions identified in our patients in CHO cells to determine their carnitine transport activity (Table 3A) . A carnitine transport activity of 20% or less than CHO expressing the wild-type OCTN2 carnitine transporter (transport activity of 100%) was considered pathogenic. Of the variants tested, 73 out of 92 were pathogenic, and 19 out of 92 were benign (Table 3A) .
Polyphen-2 and SIFT are software programs commonly used to predict the effect of missense variants on protein function. We compared the predictions of Polyphen-2 and SIFT against functional studies of carnitine transport in CHO cells (Table 3C ). Our results indicate that while Polyphen-2 and SIFT were effective in separating benign from damaging variants, they incorrectly identified the effect of variants in about 20% of the cases (Table 4) . For variants in which Polyphen-2 and SIFT provided a concordant interpretation, the effect of benign variants was wrongly predicted in 53% of the cases, while the error was reduced to 3% when predicting the effect of damaging variants (Table 4) . For these reasons, these programs seem skewed in predicting more damaging effects of missense mutations than experimentally observed (false positive results) in the OCTN2 carnitine transporter.
TA B L E 4
Correlation between functional studies and predictions of variant analysis software programs Polyphen-2 and SIFT are software programs commonly used to predict the pathogenicity of missense variants. Functional studies of carnitine transport in CHO cells expressing 90 missense variants and two in-frame deletions identified in our patients were compared to the predictions of Polyphen-2 and SIFT. Carnitine transport activity of 20% or less that the wild-type transporter was considered pathogenic. Both programs were effective in separating benign from damaging variants (P = 0.0005 for Polyphen-2 and P = 0.0009 for SIFT using Fisher exact text). However, about 20% of the variants were incorrectly predicted by either program, with a more marked error in the prediction of benign variants. Polyphen-2 and SIFT provided a concordant prediction of the effect of a variant in 80% of the cases (74 out of 92 variants). In 86% of the cases, the results provided by the two programs were concordant with the results obtained analyzing carnitine transport in CHO cells, with 57 out of 59 (97%) variants correctly identified as pathogenic, but only seven out of 15 (47%) correctly identified as benign.
We do not know whether this could extend to the interpretation of functional effects in other membrane transporters.
The incidence of primary carnitine deficiency is approximately 1:142,000 in the USA as ascertained by newborn screening (Therrell et al., 2014) . From the frequency of pathogenic alleles reported in the ExAC Browser Beta and in the gnomAD Browser in about 120,000 healthy (heterozygotes) individuals (Table 3B and Supplementary Table S1 ) (Lek et al., 2016) , the calculated frequency of mutant alleles is 1:221, with a minimal estimated frequency of people carrying two abnormal alleles in the general population of 1.6817 × 10 −5 or 1:59,465 individuals. This frequency is significantly higher than the one reported by newborn screening, indicating that some affected individuals might be missed by the current neonatal screening protocols.
We do not know whether this is due to specific mutations (Chen et al., 2013) and/or to problems related to the timing of collection of the newborn screening sample, in which the blood samples are collected at 1-3 days of age and carnitine levels might reflect those of the mother (Pasquali & Longo, 2013; Rasmussen et al., 2017; Schimmenti et al., 2007) . Carnitine is transferred from the mother to the child via the placenta, and immediately after birth levels of free carnitine (C0) are usually lower in infants of mothers with primary carnitine deficiency as compared to infants with the disease themselves (Pasquali & Longo, 2013) . With time, levels decrease in infants with primary carnitine deficiency, but remain stable or slightly increase in infants of mothers with primary carnitine deficiency (Pasquali & Longo, 2013) . The diagnosis can therefore be missed if screening is performed too close to birth and no second screening is obtained. In the Faroe Islands, post-neonatal screening (age > 2 months) was able to identify additional patients who had unrevealing newborn screening, confirming that patients with primary carnitine deficiency are missed by current newborn screening methods . For these reasons, primary carnitine deficiency should be considered in children and adults with a suitable clinical presentation (hypoglycemia, cardiomyopathy, arrhythmia, sudden death) even in the presence of a normal newborn screening test.
